Infusion Clinical Trials for New Myasthenia Gravis Treatment
Infusion for Health is deeply committed to advancing treatments for Myasthenia Gravis.
Myasthenia Gravis is a chronic autoimmune disorder that affects neuromuscular function. We are excited to participate in a pivotal clinical trial aimed at exploring new therapeutic options for this challenging condition.
Our dedicated team of medical professionals is here to support patients, healthcare providers, and sponsors throughout this important process.
Clinical Research Details for Myasthenia Gravis Trials
The clinical trial for myasthenia gravis evaluates the safety and efficacy of an investigational drug designed to reprogram the immune system and alleviate symptoms. Our research sites have been approved for this critical study, reflecting our commitment to high standards in clinical research. Our team, which includes several experienced medical directors, is dedicated to advancing treatment options for myasthenia gravis.
We are actively seeking participants who meet specific criteria, such as being between 18 and 75 years old and having a positive test for antibodies to acetylcholine receptors. Additionally, we want to connect with healthcare providers interested in referring their patients. Your involvement can significantly contribute to the success of this trial and the advancement of effective treatments for Myasthenia Gravis.
Are you interested in being involved in this groundbreaking trial?
Contact Us
About COUR
We are proud to partner with COUR Pharmaceuticals, a leader in innovative therapies targeting autoimmune diseases. COUR is sponsoring this clinical trial to evaluate the safety and efficacy of the investigational drug known as CNP-106. The main aim of their study is to determine how safe and tolerable CNP-106 is for people with Myasthenia Gravis and to see if it can improve MG symptoms.
CNP-106 Clinical Trial Details
- Participants will receive either CNP-106 or a placebo intravenously on Day 1, Day 8, and for some on Day 90.
- They are searching for people who fall within the Myasthenia Gravis Foundation of America Clinical Classification Class III-IV.
- Exclusion criteria include being in Clinical Classification Class I or V, or having received a COVID-19 vaccine within 14 days of screening or planning to receive any vaccination during the study period.
COUR’s dedication to groundbreaking research and patient care aligns perfectly with our mission at Infusion for Health. Together, we aim to bring hope and new treatment options to those living with this condition.
Learn MoreWant More Details About Our Myasthenia Gravis Clinical Trials?
Are you or a loved one struggling with Myasthenia Gravis? Are you a healthcare provider interested in referring patients?
We invite you to join us in this critical study. Your involvement can make a significant difference in advancing effective treatments for Myasthenia Gravis.
For more information or to participate, please contact Danielle at damendoza@infusionforhealth.com, or fill out the form provided. We are here to provide support and answer any questions you may have.
To learn more about the trial, please visit CNP-106 Clinical Trial Myasthenia Gravis.
